Unique ID issued by UMIN | UMIN000003132 |
---|---|
Receipt number | R000003796 |
Scientific Title | Investigation of patient satisfaction to Second-generation antihistamines in the treatment of Japanese cedar and cypress family pollinosis. |
Date of disclosure of the study information | 2010/02/03 |
Last modified on | 2016/08/29 09:49:36 |
Investigation of patient satisfaction to Second-generation antihistamines in the treatment of Japanese cedar and cypress family pollinosis.
Investigation of patient satisfaction in pollinosis to antihistamines.
Investigation of patient satisfaction to Second-generation antihistamines in the treatment of Japanese cedar and cypress family pollinosis.
Investigation of patient satisfaction in pollinosis to antihistamines.
Japan |
Japanese cedar and cypress family pollinosis
Oto-rhino-laryngology |
Others
NO
The distribution medicine is administered to two groups "Medicine of which the feature is height in the effect" and "Medicine that assumes few of drowsiness to be a feature" by the patient's hope for the pollinosis patient, and the influence and the patient satisfaction are investigated on the effect and QOL.
Efficacy
Pragmatic
Transitions of nasal symptom and ocular condition of two weeks after beginning of the treatment from first medical examination
Symptom score (stuffy nose,runny nose, sneezing,eye itchiness and tearing), medication score and QOL Questionaire score(JRQLQ No1).
Satisfaction rating to treatment.
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
From the first medical examination, administer 5 mg as olopatadine hydrochloride
twice a day orally in the morning and at bedtime , at least two weeks.
From the first medical examination, administer 60 mg as fexofenadine hydrochloride twice a day orally , at least two weeks.
20 | years-old | <= |
Not applicable |
Male and Female
(1) It is pollinosis caused by Japanese cedar or cypress pollen and a final diagnosis is a done patient.
(2) Patient judged that severity of symptoms when beginning to investigate is more than slight illness based on risk stratification of "Practical Guideline for the Management of Allergic Rhinitis in Japan(2009)"
(3) Written informed consent is required.
(1) with nasal diseases such as nasal polyps, hypertrophic rhinitis, acute chronic rhinitis, or deviated septum which cause a barrier to evaluate nasal symptoms.
(2) Patient that change of symptom is remarkable after specific immunotherapy is begun.
(3) Patient who should continuously use medicine (antiallergic drugs, antihistamine drugs, anticholinergic drugs, a complex of histamine/ Gamma-globulin preparations, vasoconstrictor drugs and antihypertensive drugs) that influences when effect of drug evaluation.
(5) Pregnancy, potential pregnancy, and breast-feeding patient.
(6) the others, inappropriate to this study by the judgment of doctor.
300
1st name | |
Middle name | |
Last name | Eriko Hoshi |
Shiga University of Medical Science
Department of Otorhinolaryngology
Seta Tsukinowa-cho, Otsu City, Shiga, JAPAN
077-541-2261
1st name | |
Middle name | |
Last name |
Shiga University of Medical Science
Department of Otorhinolaryngology
077-541-2261
Department of Otorhinolaryngology , Shiga University of Medical Science
None
Self funding
Japan
NO
2010 | Year | 02 | Month | 03 | Day |
Unpublished
Completed
2009 | Year | 12 | Month | 01 | Day |
2010 | Year | 02 | Month | 01 | Day |
2010 | Year | 05 | Month | 01 | Day |
2016 | Year | 08 | Month | 29 | Day |
2016 | Year | 08 | Month | 29 | Day |
2016 | Year | 08 | Month | 29 | Day |
2010 | Year | 02 | Month | 02 | Day |
2016 | Year | 08 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003796